Vegenics files for IND for anti-cancer drug
Tuesday, 04 October, 2011
Vegenics, a fully-owned subsidiary of Circadian (ASX:CIR), has reached a milestone in its development of its treatment for cancer patients with solid tumours, VGX-100, with it submitting an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
VGX-100 is an human antibody that targets the VGEF-C protein and is being developed to treat glioblastoma, metastatic colorectal and other cancers. It is also being developed as an agent to treat dry eye disease.
Preclincial animal model studies by Vegenics have shown that VGX-100, combined with Avastin and chemotherapy, can significantly reduce tumour growth and tumour spread as well as significantly improve tumour inhibition across a wide range of tumour types.
Phase I trials will involve the treatment of a variety of different cancer types in patients with late-stage cancer.
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
